A
Agilent Technologies, Inc.
A has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over A overall, supported by stronger fundamentals and stronger modeled upside.
A Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Healthy |
A's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
A PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 26x | $173 | — |
| Cheap | 28x | $141 | -19% |
| Fair | 31x | $160 | -7.6% |
| Current | 34x | $173 | — |
| Expensive | 45x | $227 | +31% |
Historical ranges are pointers, not guarantees.
A's PE is in its fair range at 34x. If earnings grow as analysts expect, today's price would be 26x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over A in the historical PE scenario, which offers more potential upside but is not a forecast.
A Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for A, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
A Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.70 | +32% |
| Q3 2026 | $5.08 | +19% |
| Q2 2026 | $4.98 | +23% |
| Q1 2026 | $4.53 | +3.9% |
| Q4 2025 | $4.57 | +3.2% |
| Q3 2025 | $4.27 | -11% |
| Q2 2025 | $4.06 | -3.6% |
| Q1 2025 | $4.36 | +4.3% |
| Q4 2024 | $4.43 | +5.7% |
A has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
A Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +8.1% |
| Q2 2026 | $1.8B | +10% |
| Q1 2026 | $1.8B | +7% |
| Q4 2025 | $1.9B | +9.4% |
| Q3 2025 | $1.7B | +10% |
| Q2 2025 | $1.7B | +6% |
| Q1 2025 | $1.7B | +1.4% |
| Q4 2024 | $1.7B | +0.8% |
A's revenue has grown year over year for eight quarters in a row: $1.9B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +2.9 points |
| Q2 2026 | 22% | +3.8 points |
| Q1 2026 | 20% | -2.7 points |
| Q4 2025 | 24% | -0.2 points |
| Q3 2025 | 21% | -0.4 points |
| Q2 2025 | 18% | -5.1 points |
| Q1 2025 | 22% | -0.8 points |
| Q4 2024 | 24% | -0.2 points |
A has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over A on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
A Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $439M | +69% |
| Q2 2026 | $201M | +88% |
| Q1 2026 | $175M | -48% |
| Q4 2025 | $452M | +16% |
| Q3 2025 | $259M | -28% |
| Q2 2025 | $107M | -53% |
| Q1 2025 | $334M | -15% |
| Q4 2024 | $388M | -10% |
A generated $1.3B in free cash flow over the past year, up 16% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over A on cash flow, with more consistent year-over-year improvement.
A Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -0.7% | -2M shares |
| 3 years | -4.1% | -12M shares |
| 5 years | -7.5% | -23M shares |
| Available history | -11% | -35M shares |
A has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $78M |
| Q2 2026 | $65M |
| Q1 2026 | $152M |
| Q4 2025 | $85M |
| Q3 2025 | $85M |
| Q2 2025 | $165M |
| Q1 2025 | $90M |
| Q4 2024 | $335M |
A spent $380M buying back its own shares over the past year, down 44% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
A Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.2x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.2x | Healthy |
A's net debt is about 1.1 years of its operating earnings (EBITDA), about the same as a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over A on leverage, with a lower net debt burden relative to earnings.
A Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.7 | Neutral |
| Stochastic | 80.4 | Overbought |
A's weekly RSI is 68 (neutral) and its Stochastic is 80 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
A PE vs Healthcare Sector
| Metric | A | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 32% above |
| PE % | 65 | 29 | 36 pts above |
A is trading at 34x earnings, a 32% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over A on valuation relative to its sector.
A Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $172.5 | 0.3% above |
| 20 week MA | $155.7 | 11% above |
| 50 week MA | $138.1 | 25% above |
| 100 week MA | $132.5 | 31% above |
| 200 week MA | $132.5 | 31% above |
A has climbed back above all five of its weekly moving averages, and it's now 31% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
A Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $85.4 | $117.3 | +37% |
| 2021 | $117.3 | $157.8 | +35% |
| 2022 | $157.8 | $149.2 | -5.4% |
| 2023 | $149.2 | $139.0 | -6.8% |
| 2024 | $139.0 | $135.5 | -2.5% |
| 2025 | $135.5 | $138.4 | +2.1% |
| 2026 YTD | $138.4 | $173.0 | +25% |
A has finished lower in three of the last six years. It's up 25% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over A on returns for 2026, with the stronger performance.